NEW YORK, NY, November 2, 2020 - Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation. The agreement includes an upfront payment of $575

NEW YORK , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the closing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering at a price to the public of $42.00 per

NEW YORK , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced that it will report its third quarter 2020 financial results on Wednesday, November 11, 2020 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00

NEW YORK, NY – October 15, 2020 – Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the pricing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering pursuant to a registration statement on Form S-1

NEW YORK , Oct. 15, 2020 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2020 of $0.15 per class A share. The dividend will be paid on December 15, 2020 , to shareholders of record at the close of

NEW YORK , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today that certain selling shareholders intend to offer an aggregate 17,343,037 of the Company's Class A ordinary shares in an underwritten public offering.

NEW YORK, NY – September 2, 2020 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has closed an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, the “Notes”): $1 billion aggregate principal amount of 0.75% Senior Notes due 2023; $1 billion

NEW YORK, NY, September 2, 2020 - The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2020 of $0.15 per class A share. The dividend will be paid on September 30, 2020, to shareholders of record at the close of business on

NEW YORK, NY - August 25, 2020 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, the “Notes”): $1 billion aggregate principal amount of 0.75% Senior Notes due 2023; $1 billion aggregate

NEW YORK (NY) - August 19, 2020 – Royalty Pharma plc announced today that it intends to offer, subject to market and other conditions, senior unsecured notes in multiple tranches (the “Notes”) in a private offering exempt from registration in accordance with Rule 144A and Regulation S under the